Riesco-Martinez, Maria Carmen
Capdevila, Jaume http://orcid.org/0000-0003-0718-8619
Alonso, Vicente
Jimenez-Fonseca, Paula
Teule, Alex http://orcid.org/0000-0003-0028-7200
Grande, Enrique
Sevilla, Isabel
Benavent, Marta
Alonso-Gordoa, Teresa
Custodio, Ana
Anton-Pascual, Beatriz
Hernando, Jorge
Polo, Eduardo
Castillo-Trujillo, Oscar Alfredo
Lamas-Paz, Arantza http://orcid.org/0000-0001-5857-4320
Teijo, Ana http://orcid.org/0000-0002-8280-8446
Rodriguez-Gil, Yolanda
Soldevilla, Beatriz
Garcia-Carbonero, Rocio http://orcid.org/0000-0002-3342-397X
Article History
Received: 8 February 2024
Accepted: 26 July 2024
First Online: 8 August 2024
Competing interests
: RGC has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from AAA, Advanz Pharma, Amgen, Astellas, Bayer, BMS, Boerhringer, Esteve, GSK, Hutchmed, Ipsen, Midatech Pharma, MSD, Novartis, PharmaMar, Servier, Takeda, and has received research support from Pfizer, BMS and MSD. EG has received honoraria for speaker engagements, advisory roles or funding of continuous medical education from Adacap, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, and Thermo Fisher Scientific. EG has received research grants from Pfizer, Astra Zeneca, Astellas, and Lexicon Pharmaceuticals. TA-G declares participating in advisory boards for Astellas, Bayer, Bristol Myers Squibb, EISAI, IPSEN, Lilly, Novartis Advanced Accelerator Applications, Pfizer, Roche, and Sanofi; act as invited speaker for Janssen-Cilag; and being project lead for Johnson & Johnson, IPSEN and Pfizer. JC declares scientific consultancy role (speaker and advisory roles) for Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, Lilly, Hudchmed, ITM, Merck Serono, Roche, Esteve, Advanz; and received research grants from Novartis, Pfizer, Astrazeneca, Advanced Accelerator Applications, Eisai, Amgen, ITM and Bayer. PJ-F has provided scientific advice and/or received honoraria from Astellas, BMS, Eisai, Lilly, MSD, Pfizer and Rovi. IS received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AAA, Novartis, Pharmamar, Ipsen, Pfizer, Amgen,Bayer; support for attending meetings and/or travel from AAA, Novartis, Pharmamar, Ipsen, Boehringer, Advanz Pharma, Esteve Pharmaceuticals, Amgen, Bayer; and participated on a Data Safety Monitoring Board or Advisory Board for AAA, Novartis, Pharmamar, Ipsen, Boehringer, Advanz Pharma, Esteve Pharmaceuticals, Amgen, Bayer. AT received support for attending meetings and /or travel from MSD, Roche; received payment honoraria for lectures/scientific advice from Pfizer and Diaceutics; and working as an employee at MD Anderson Hospital. All the remaining co-authors state that they do not have conflict of interest.